nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—colon cancer	0.793	1	CbGaD
Fidaxomicin—ABCB1—Irinotecan—colon cancer	0.0602	0.416	CbGbCtD
Fidaxomicin—ABCB1—Vincristine—colon cancer	0.0526	0.364	CbGbCtD
Fidaxomicin—ABCB1—Methotrexate—colon cancer	0.0319	0.22	CbGbCtD
Fidaxomicin—Megacolon—Irinotecan—colon cancer	0.00888	0.142	CcSEcCtD
Fidaxomicin—Megacolon—Methotrexate—colon cancer	0.00443	0.0709	CcSEcCtD
Fidaxomicin—Intestinal obstruction—Vincristine—colon cancer	0.0022	0.0352	CcSEcCtD
Fidaxomicin—Intestinal obstruction—Irinotecan—colon cancer	0.00214	0.0342	CcSEcCtD
Fidaxomicin—Platelet count decreased—Capecitabine—colon cancer	0.00164	0.0263	CcSEcCtD
Fidaxomicin—Intestinal obstruction—Capecitabine—colon cancer	0.00143	0.0229	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.00106	0.0169	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00101	0.0162	CcSEcCtD
Fidaxomicin—Abdominal distension—Irinotecan—colon cancer	0.000921	0.0147	CcSEcCtD
Fidaxomicin—Neutropenia—Vincristine—colon cancer	0.000878	0.0141	CcSEcCtD
Fidaxomicin—Dysphagia—Fluorouracil—colon cancer	0.000876	0.014	CcSEcCtD
Fidaxomicin—Neutropenia—Irinotecan—colon cancer	0.000855	0.0137	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000708	0.0113	CcSEcCtD
Fidaxomicin—Immune system disorder—Irinotecan—colon cancer	0.000661	0.0106	CcSEcCtD
Fidaxomicin—Flatulence—Irinotecan—colon cancer	0.000628	0.0101	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000625	0.01	CcSEcCtD
Fidaxomicin—Abdominal distension—Capecitabine—colon cancer	0.000616	0.00987	CcSEcCtD
Fidaxomicin—Dysphagia—Capecitabine—colon cancer	0.000612	0.0098	CcSEcCtD
Fidaxomicin—Anaemia—Vincristine—colon cancer	0.000605	0.00969	CcSEcCtD
Fidaxomicin—Anaemia—Irinotecan—colon cancer	0.000589	0.00943	CcSEcCtD
Fidaxomicin—Neutropenia—Capecitabine—colon cancer	0.000572	0.00917	CcSEcCtD
Fidaxomicin—Anaemia—Fluorouracil—colon cancer	0.000564	0.00903	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Capecitabine—colon cancer	0.000552	0.00884	CcSEcCtD
Fidaxomicin—Nervous system disorder—Vincristine—colon cancer	0.000524	0.00839	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Capecitabine—colon cancer	0.000516	0.00827	CcSEcCtD
Fidaxomicin—Nervous system disorder—Irinotecan—colon cancer	0.00051	0.00817	CcSEcCtD
Fidaxomicin—Nervous system disorder—Fluorouracil—colon cancer	0.000489	0.00782	CcSEcCtD
Fidaxomicin—Decreased appetite—Vincristine—colon cancer	0.000464	0.00743	CcSEcCtD
Fidaxomicin—Dyspnoea—Irinotecan—colon cancer	0.000464	0.00743	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Vincristine—colon cancer	0.000461	0.00738	CcSEcCtD
Fidaxomicin—Dyspepsia—Irinotecan—colon cancer	0.000458	0.00733	CcSEcCtD
Fidaxomicin—Constipation—Vincristine—colon cancer	0.000457	0.00731	CcSEcCtD
Fidaxomicin—Decreased appetite—Irinotecan—colon cancer	0.000452	0.00724	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Irinotecan—colon cancer	0.000449	0.00719	CcSEcCtD
Fidaxomicin—Constipation—Irinotecan—colon cancer	0.000445	0.00712	CcSEcCtD
Fidaxomicin—Dyspnoea—Fluorouracil—colon cancer	0.000444	0.00711	CcSEcCtD
Fidaxomicin—Immune system disorder—Capecitabine—colon cancer	0.000443	0.00709	CcSEcCtD
Fidaxomicin—Dyspepsia—Fluorouracil—colon cancer	0.000439	0.00702	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vincristine—colon cancer	0.000437	0.00699	CcSEcCtD
Fidaxomicin—Decreased appetite—Fluorouracil—colon cancer	0.000433	0.00693	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00043	0.00689	CcSEcCtD
Fidaxomicin—Malnutrition—Capecitabine—colon cancer	0.000427	0.00683	CcSEcCtD
Fidaxomicin—Neutropenia—Methotrexate—colon cancer	0.000426	0.00682	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Irinotecan—colon cancer	0.000425	0.00681	CcSEcCtD
Fidaxomicin—Abdominal pain—Vincristine—colon cancer	0.000422	0.00676	CcSEcCtD
Fidaxomicin—Flatulence—Capecitabine—colon cancer	0.00042	0.00673	CcSEcCtD
Fidaxomicin—Dysgeusia—Capecitabine—colon cancer	0.000418	0.00669	CcSEcCtD
Fidaxomicin—Abdominal pain—Irinotecan—colon cancer	0.000411	0.00658	CcSEcCtD
Fidaxomicin—Anaemia—Capecitabine—colon cancer	0.000394	0.00631	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vincristine—colon cancer	0.000394	0.0063	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Methotrexate—colon cancer	0.000384	0.00615	CcSEcCtD
Fidaxomicin—Hypersensitivity—Irinotecan—colon cancer	0.000383	0.00614	CcSEcCtD
Fidaxomicin—Hypersensitivity—Fluorouracil—colon cancer	0.000367	0.00588	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000361	0.00578	CcSEcCtD
Fidaxomicin—Dry mouth—Capecitabine—colon cancer	0.000355	0.00569	CcSEcCtD
Fidaxomicin—Dizziness—Vincristine—colon cancer	0.000353	0.00566	CcSEcCtD
Fidaxomicin—Pruritus—Fluorouracil—colon cancer	0.000352	0.00564	CcSEcCtD
Fidaxomicin—Dizziness—Irinotecan—colon cancer	0.000344	0.00551	CcSEcCtD
Fidaxomicin—Nervous system disorder—Capecitabine—colon cancer	0.000341	0.00547	CcSEcCtD
Fidaxomicin—Vomiting—Vincristine—colon cancer	0.00034	0.00544	CcSEcCtD
Fidaxomicin—Skin disorder—Capecitabine—colon cancer	0.000338	0.00541	CcSEcCtD
Fidaxomicin—Rash—Vincristine—colon cancer	0.000337	0.00539	CcSEcCtD
Fidaxomicin—Dermatitis—Vincristine—colon cancer	0.000336	0.00539	CcSEcCtD
Fidaxomicin—Headache—Vincristine—colon cancer	0.000335	0.00536	CcSEcCtD
Fidaxomicin—Vomiting—Irinotecan—colon cancer	0.000331	0.0053	CcSEcCtD
Fidaxomicin—Immune system disorder—Methotrexate—colon cancer	0.00033	0.00528	CcSEcCtD
Fidaxomicin—Dizziness—Fluorouracil—colon cancer	0.000329	0.00528	CcSEcCtD
Fidaxomicin—Rash—Irinotecan—colon cancer	0.000328	0.00525	CcSEcCtD
Fidaxomicin—Dermatitis—Irinotecan—colon cancer	0.000328	0.00525	CcSEcCtD
Fidaxomicin—Headache—Irinotecan—colon cancer	0.000326	0.00522	CcSEcCtD
Fidaxomicin—Malnutrition—Methotrexate—colon cancer	0.000318	0.00508	CcSEcCtD
Fidaxomicin—Nausea—Vincristine—colon cancer	0.000317	0.00508	CcSEcCtD
Fidaxomicin—Vomiting—Fluorouracil—colon cancer	0.000317	0.00507	CcSEcCtD
Fidaxomicin—Rash—Fluorouracil—colon cancer	0.000314	0.00503	CcSEcCtD
Fidaxomicin—Dermatitis—Fluorouracil—colon cancer	0.000314	0.00503	CcSEcCtD
Fidaxomicin—Headache—Fluorouracil—colon cancer	0.000312	0.005	CcSEcCtD
Fidaxomicin—Dysgeusia—Methotrexate—colon cancer	0.000311	0.00498	CcSEcCtD
Fidaxomicin—Dyspnoea—Capecitabine—colon cancer	0.00031	0.00497	CcSEcCtD
Fidaxomicin—Nausea—Irinotecan—colon cancer	0.000309	0.00495	CcSEcCtD
Fidaxomicin—Dyspepsia—Capecitabine—colon cancer	0.000306	0.00491	CcSEcCtD
Fidaxomicin—Decreased appetite—Capecitabine—colon cancer	0.000303	0.00485	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Capecitabine—colon cancer	0.000301	0.00481	CcSEcCtD
Fidaxomicin—Constipation—Capecitabine—colon cancer	0.000298	0.00477	CcSEcCtD
Fidaxomicin—Nausea—Fluorouracil—colon cancer	0.000296	0.00474	CcSEcCtD
Fidaxomicin—Anaemia—Methotrexate—colon cancer	0.000294	0.0047	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Capecitabine—colon cancer	0.000285	0.00456	CcSEcCtD
Fidaxomicin—Abdominal pain—Capecitabine—colon cancer	0.000275	0.00441	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000269	0.0043	CcSEcCtD
Fidaxomicin—Hypersensitivity—Capecitabine—colon cancer	0.000257	0.00411	CcSEcCtD
Fidaxomicin—Nervous system disorder—Methotrexate—colon cancer	0.000254	0.00407	CcSEcCtD
Fidaxomicin—Skin disorder—Methotrexate—colon cancer	0.000252	0.00403	CcSEcCtD
Fidaxomicin—Pruritus—Capecitabine—colon cancer	0.000246	0.00394	CcSEcCtD
Fidaxomicin—Dyspnoea—Methotrexate—colon cancer	0.000231	0.0037	CcSEcCtD
Fidaxomicin—Dizziness—Capecitabine—colon cancer	0.00023	0.00369	CcSEcCtD
Fidaxomicin—Dyspepsia—Methotrexate—colon cancer	0.000228	0.00365	CcSEcCtD
Fidaxomicin—Decreased appetite—Methotrexate—colon cancer	0.000225	0.00361	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Methotrexate—colon cancer	0.000224	0.00358	CcSEcCtD
Fidaxomicin—Vomiting—Capecitabine—colon cancer	0.000221	0.00354	CcSEcCtD
Fidaxomicin—Rash—Capecitabine—colon cancer	0.00022	0.00351	CcSEcCtD
Fidaxomicin—Dermatitis—Capecitabine—colon cancer	0.000219	0.00351	CcSEcCtD
Fidaxomicin—Headache—Capecitabine—colon cancer	0.000218	0.00349	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Methotrexate—colon cancer	0.000212	0.00339	CcSEcCtD
Fidaxomicin—Nausea—Capecitabine—colon cancer	0.000207	0.00331	CcSEcCtD
Fidaxomicin—Abdominal pain—Methotrexate—colon cancer	0.000205	0.00328	CcSEcCtD
Fidaxomicin—Hypersensitivity—Methotrexate—colon cancer	0.000191	0.00306	CcSEcCtD
Fidaxomicin—Pruritus—Methotrexate—colon cancer	0.000183	0.00294	CcSEcCtD
Fidaxomicin—Dizziness—Methotrexate—colon cancer	0.000171	0.00274	CcSEcCtD
Fidaxomicin—Vomiting—Methotrexate—colon cancer	0.000165	0.00264	CcSEcCtD
Fidaxomicin—Rash—Methotrexate—colon cancer	0.000163	0.00262	CcSEcCtD
Fidaxomicin—Dermatitis—Methotrexate—colon cancer	0.000163	0.00261	CcSEcCtD
Fidaxomicin—Headache—Methotrexate—colon cancer	0.000162	0.0026	CcSEcCtD
Fidaxomicin—Nausea—Methotrexate—colon cancer	0.000154	0.00246	CcSEcCtD
